A Study to Establish a Platform for Managing Pancreatic Adenocarcinoma Using Patient-derived Tumoroids

Overview

NCT ID: NCT04821219

About this study

The purposes of this study are to determine the optimal patient-derived tumoroid (PDT) model, to determine the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach, to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish PDT as a platform for a personalized approach to guide multimodality treatment. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years of age.
  • Have an ECOG Performance Status of ≤ 2.
  • No evidence of distant metastasis on imaging.
  • Histologic or cytologic proven adenocarcinoma of the pancreas.
  • Providing informed consent prior to enrollment in the trial.

Exclusion Criteria:

  • < 18 years of age.
  • Failure to obtain additional core needle biopsies for generating PDTs.
  • Patients who received chemotherapy in the past 5 years.
  • Females who are pregnant or plan to become pregnant.

More information

Publications

Publications are currently not available
.
CLS-20510163

Mayo Clinic Footer